UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Volltextzugriff (PDF)

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-12, Vol.29 (34), p.4574-4580

2011

Volltextzugriff (PDF)

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2523-2529

2009

Volltextzugriff (PDF)

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Volltextzugriff (PDF)

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

The Journal of nuclear medicine (1978), 2023-10, Vol.64 (10), p.1540-1549

2023

Volltextzugriff (PDF)

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4007-4014

2015

Volltextzugriff (PDF)

Multimodal treatment of non-small-cell lung cancer

The Lancet (British edition), 2015-09, Vol.386 (9998), p.1018-1020

2015

Volltextzugriff (PDF)

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer

The Journal of thoracic and cardiovascular surgery, 2010-06, Vol.139 (6), p.1424-1430

2010

Volltextzugriff (PDF)

Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy

Journal of Nuclear Medicine, 2021-12, Vol.62 (12), p.1684-1691

2021

Volltextzugriff (PDF)

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2667-2674

2011

Volltextzugriff (PDF)

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements

Current opinion in oncology, 2014-03, Vol.26 (2), p.171-181

2014

Volltextzugriff (PDF)

Surgery in stage III non-small-cell lung cancer

The Lancet (British edition), 2009-08, Vol.374 (9687), p.359-360

2009

Volltextzugriff (PDF)

Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors

Technology in cancer research & treatment, 2018-01, Vol.17

2018

Volltextzugriff (PDF)

Fibroblast Activation Protein-Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

Journal of Nuclear Medicine, 2024-08, Vol.65 (8), p.1188-1193

2024

Volltextzugriff (PDF)

68 Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

Journal of Nuclear Medicine, 2023-10, Vol.64 (10), p.1540-1549

2023

Volltextzugriff (PDF)

Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT126-CT126

2017

Volltextzugriff (PDF)

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY

The Journal of nuclear medicine (1978), 2021-05

2021

Volltextzugriff (PDF)

Abstract B6: Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in non-small cell lung cancer (NSCLC)

Clinical cancer research, 2012-02, Vol.18 (3_Supplement), p.B6-B6

2012

Volltextzugriff (PDF)

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. Commentary

The Journal of thoracic and cardiovascular surgery, 2010, Vol.139 (6), p.1424-1430

2010

Volltextzugriff (PDF)

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As FirstLine Treatment for Advanced Non―Small-Cell Lung Cancer

Journal of clinical oncology, 2011, Vol.29 (19), p.2667-2674

2011

Volltextzugriff (PDF)

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

The Lancet (British edition), 2009-05, Vol.373 (9674), p.1525-1531

2009

Volltextzugriff (PDF)

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Annals of oncology, 2011-07, Vol.22 (7), p.1507-1519

2011

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4794-4805

2012

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

KollektionPublisher website

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Humans
(16)
Female
(12)
Lung Neoplasms - Drug Therapy
(12)
Male
(12)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(11)
Middle Aged
(11)
Aged
(10)
Oncology
(10)
Adult
(9)
Biological And Medical Sciences
(8)
Lung Neoplasms - Pathology
(8)
Medical Sciences
(8)
Tumors
(8)
Lung Cancer
(7)
Carcinoma, Non-Small-Cell Lung - Mortality
(6)
Carcinoma, Non-Small-Cell Lung - Pathology
(6)
Lung Neoplasms - Mortality
(6)
Pneumology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Multimodal treatment of non-small-cell lung cancer

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer

Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements

Surgery in stage III non-small-cell lung cancer

Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors

Fibroblast Activation Protein-Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial

68 Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063

PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY

Abstract B6: Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in non-small cell lung cancer (NSCLC)

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. Commentary

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As FirstLine Treatment for Advanced Non―Small-Cell Lung Cancer

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Aktive Filter

Suchergebnisse filtern